Gastrointestinal Cancer Market Report 2026

Gastrointestinal Cancer Market Overview

• Gastrointestinal Cancer market size has reached to $27.05 billion in 2025 • Expected to grow to $47.4 billion in 2030 at a compound annual growth rate (CAGR) of 11.8% • Growth Driver: Rising Adoption Of Targeted Therapies Is Fueling The Growth Of The Market Due To Their Precision In Attacking Cancer Cells While Minimizing Harm To Healthy Tissue • Market Trend: Breakthrough Monoclonal Antibody Therapies With Advance Treatment Of HER2-Negative Gastric And GEJ Adenocarcinoma • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Gastrointestinal Cancer Market?

Gastrointestinal (GI) cancer refers to a group of cancers that affect the digestive system, including the esophagus, stomach, liver, pancreas, gallbladder, small intestine, colon, and rectum. These cancers develop when abnormal cells grow uncontrollably in the GI tract. The main goal of GI cancer treatment is to eliminate or control the spread of cancer, relieve symptoms, and improve quality of life. The main types of gastrointestinal cancer are colorectal cancer, stomach cancer, esophageal cancer, pancreatic cancer, liver cancer, and others. Colorectal cancer is a malignancy of the colon or rectum, primarily driven by genetic and lifestyle factors, enabling targeted screening and treatment within gastrointestinal oncology. It is treated with various diagnostics such as endoscopy, biopsy, molecular diagnostics, imaging, and others with several treatments including chemotherapy, immunotherapy, targeted therapy, radiation therapy, surgery, and others, and is used by various end-users such as hospitals, oncology centers, research institutes, diagnostic laboratories, and others.

What Is The Gastrointestinal Cancer Market Growth Forecast?

The gastrointestinal cancer market size is expected to see rapid growth in the next few years. It will grow to $47.4 billion in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to increasing investments in personalized oncology, rising adoption of biomarker-based diagnostics, expansion of immuno-oncology pipelines, growing use of minimally invasive diagnostics, increasing healthcare expenditure on cancer care. Major trends in the forecast period include increasing adoption of targeted gi cancer therapies, rising use of molecular diagnostics, growing focus on immunotherapy combinations, expansion of early cancer screening programs, enhanced integration of precision medicine.

Global Gastrointestinal Cancer Market Segmentation

1) By Cancer Type: Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Liver Cancer, Other Cancer Types 2) By Diagnostics: Endoscopy, Biopsy, Molecular Diagnostics, Imaging, Other Diagnostics 3) By Treatment: Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery, Other Treatments 4) By End-User: Hospitals, Oncology Centers, Research Institutes, Diagnostic Laboratories, Other End-Users Subsegments: 1) By Colorectal Cancer: Colon Cancer, Rectal Cancer, Recurrent Colorectal Cancer, Metastatic Colorectal Cancer 2) By Stomach Cancer: Adenocarcinoma, Gastrointestinal Stromal Tumors (GIST), Lymphoma, Carcinoid Tumors 3) By Esophageal Cancer: Adenocarcinoma, Squamous Cell Carcinoma, Small Cell Carcinoma, Other Rare Esophageal Tumors 4) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Endocrine (Neuroendocrine) Pancreatic Tumors, Metastatic Pancreatic Cancer, Resectable Or Unresectable Tumors 5) By Liver Cancer: Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma, Hepatoblastoma, Secondary (Metastatic) Liver Cancer 6) By Other Cancer Types: Small Intestine Cancer, Anal Cancer, Gallbladder Cancer, Gastrointestinal Carcinoid Tumor

What Is The Driver Of The Gastrointestinal Cancer Market?

The rising adoption of targeted therapies is expected to propel the growth of the gastrointestinal cancer market going forward. Targeted therapies are treatments that precisely block cancer cell growth by acting on specific molecular targets, reducing harm to normal, healthy cells. Targeted therapies are designed to act on specific molecular pathways or genetic mutations driving a disease, especially in cancer. Unlike traditional treatments like chemotherapy, which attack both healthy and diseased cells, targeted therapies focus on the unique characteristics of a patient's condition. Targeted therapies for gastrointestinal (GI) cancer act on specific genes or proteins that control tumor growth, enabling precise and effective treatment. This results in better outcomes with fewer side effects than conventional chemotherapy. For instance, in July 2023, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, at the end of quarter one (Q1) 2023, there were 247 gene therapies in Phase II, this number rose by 5% to reach 260 by the end of quarter two (Q2). Therefore, the rising adoption of targeted therapies is driving the growth of the gastrointestinal cancer industry.

Key Players In The Global Gastrointestinal Cancer Market

Major companies operating in the gastrointestinal cancer market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol‑Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Ipsen Biopharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Boehringer Ingelheim International GmbH, Zai Lab Limited, Taiho Pharmaceutical Co. Ltd

Global Gastrointestinal Cancer Market Trends and Insights

Major companies operating in the gastrointestinal cancer market are focused on developing advanced solutions, such as monoclonal antibody treatment, to improve patient survival rates and minimize treatment-related side effects. Monoclonal antibody treatment involves using laboratory-produced antibodies that precisely identify and attach to cancer cells, assisting the immune system in targeting and eliminating them. For instance, in September 2024, Astellas Pharma Inc., a Japan-based pharmaceutical company, launched VYLOY (zolbetuximab) in combination with fluoropyrimidine- and platinum-containing chemotherapy, which received approval from the European Commission. It is a first-line treatment for adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express claudin 18.2 (CLDN18.2). This approval makes VYLOY the first and only therapy in the European Union targeting CLDN18.2, a biomarker in about 38% of these patients, based on positive clinical trial data from the SPOTLIGHT and GLOW studies.

What Are Latest Mergers And Acquisitions In The Gastrointestinal Cancer Market?

In February 2025, GSK plc, a UK-based pharmaceutical and biotechnology company, acquired IDRx Inc. for approximately $1.15 billion. With this acquisition, GSK aims to strengthen its immunology and infectious disease pipeline, accelerate the development of innovative therapies, and expand its capabilities in precision medicine to better address unmet medical needs. IDRx Inc. is a US-based clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of gastrointestinal stromal tumors (GIST).

Regional Outlook

North America was the largest region in the gastrointestinal cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Gastrointestinal Cancer Market?

The gastrointestinal cancer market consists of revenues earned by entities by providing services such as genetic counseling and testing, palliative and supportive care, nutrition and dietary support, rehabilitation services, and follow-up and survivorship programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastrointestinal cancer market includes sales of laparoscopic instruments, robotic surgery systems, pain management medications, and monitoring tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Gastrointestinal Cancer Market Report 2026?

The gastrointestinal cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the gastrointestinal cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.